Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPension (IS)Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repaymentsWages, Salaries and Other
Ratios

Harvard Bioscience (HBIO) Accumulated Depreciation & Amortization (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Accumulated Depreciation & Amortization for 16 consecutive years, with $18.1 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 14.51% to $18.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.1 million through Dec 2025, up 14.51% year-over-year, with the annual reading at $18.1 million for FY2025, 14.51% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $18.1 million at Harvard Bioscience, up from $15.8 million in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $18.1 million in Q4 2025, with the low at $14.4 million in Q4 2023.
  • Average Accumulated Depreciation & Amortization over 5 years is $15.5 million, with a median of $14.8 million recorded in 2022.
  • The sharpest move saw Accumulated Depreciation & Amortization dropped 12.94% in 2021, then increased 14.51% in 2025.
  • Over 5 years, Accumulated Depreciation & Amortization stood at $14.4 million in 2021, then grew by 2.75% to $14.8 million in 2022, then dropped by 3.11% to $14.4 million in 2023, then grew by 9.98% to $15.8 million in 2024, then grew by 14.51% to $18.1 million in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $18.1 million, $15.8 million, and $14.4 million for Q4 2025, Q4 2024, and Q4 2023 respectively.